Related content

Double-blind study of zotepine vs haloperidol in schizophrenia

By Petit M.   Raniwalla J.   Leutenegger E.   Tweed J.A.   Kelly F.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 333-333

Elsevier

Access to resources Recommend Favorite

Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of Depression: A 6-Month Double-Blind Study in a Primary-Care Setting in France

By Boyer P.  

PharmacoEconomics, Vol. 13, Iss. 1 Part 2, 1998-01 ,pp. : 157-169

Adis International

Access to resources Recommend Favorite

The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension

By Tremblay Angelo   Chaput Jean-Philippe   Bérubé-Parent Sonia   Prud’homme Denis   Leblanc Claude   Alméras Natalie   Després Jean-Pierre  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 123-134

Springer Publishing Company

Access to resources Recommend Favorite

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

By Poyurovsky M.   Koren D.   Gonopolsky I.   Schneidman M.   Fuchs C.   Weizman A.   Weizman R.  

European Neuropsychopharmacology, Vol. 13, Iss. 2, 2003-03 ,pp. : 123-128

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

By Buynak Robert   Shapiro Douglas Y   Okamoto Akiko   Hove Ilse Van   Rauschkolb Christine   Steup Achim   Lange Bernd   Lange Claudia   Etropolski Mila  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1787-1804

Informa Healthcare

Access to resources Recommend Favorite